Menu
GeneBe

rs786204548

Variant summary

Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PS1_ModeratePM2PP5_Very_Strong

The NM_000051.4(ATM):c.3G>A(p.Met1?) variant causes a start lost change. The variant allele was found at a frequency of 0.00000248 in 1,613,332 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (โ˜…โ˜…).

Frequency

Genomes: ๐‘“ 0.000013 ( 0 hom., cov: 32)
Exomes ๐‘“: 0.0000014 ( 0 hom. )

Consequence

ATM
NM_000051.4 start_lost

Scores

5
8
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:13

Conservation

PhyloP100: 7.11
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 20 ACMG points.

PVS1
Start lost variant, no new inframe start found.
PS1
Another start lost variant in NM_000051.4 (ATM) was described as [Pathogenic] in ClinVar as 187275
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-108227627-G-A is Pathogenic according to our data. Variant chr11-108227627-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 188901.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-108227627-G-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
ATMNM_000051.4 linkuse as main transcriptc.3G>A p.Met1? start_lost 2/63 ENST00000675843.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ATMENST00000675843.1 linkuse as main transcriptc.3G>A p.Met1? start_lost 2/63 NM_000051.4 P1

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
151944
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000242
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000398
AC:
1
AN:
251388
Hom.:
0
AF XY:
0.00
AC XY:
0
AN XY:
135866
show subpopulations
Gnomad AFR exome
AF:
0.0000615
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000137
AC:
2
AN:
1461388
Hom.:
0
Cov.:
30
AF XY:
0.00
AC XY:
0
AN XY:
727050
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000180
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000132
AC:
2
AN:
151944
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74198
show subpopulations
Gnomad4 AFR
AF:
0.0000242
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000147
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000329
Hom.:
0
Bravo
AF:
0.0000113
ExAC
AF:
0.00000824
AC:
1
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingAthena DiagnosticsJan 20, 2021The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant is expected to interfere with initiation of protein synthesis. This variant has been identified in multiple unrelated individuals with clinical features associated with this gene, including both ataxia-telangiectasia (A-T) and cancer patients (PMID: 12552559, 28779002, 28767289, 31285527). -
Pathogenic, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoJan 20, 2021This variant disrupts the translation initiation codon of the ATM mRNA and is predicted to interfere with ATM protein synthesis. The frequency of this variant in the general population, 0.000062 (1/16252 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in one individual with pancreatic cancer (PMIDs:28767289 (2017) and 31285527 (2019)), and two individuals with breast cancer (PMID:28779002 (2017)). Based on the available information, this variant is classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingGeneDxMar 29, 2023Initiation codon variant in a gene for which loss-of-function is a known mechanism of disease; Observed in the compound heterozygous state in individuals with ataxia telangiectasia (Buzin et al., 2003); Observed in individuals with breast and pancreatic cancer (Decker et al., 2017; Shindo et al., 2017; Hutchings et al., 2019; Dorling et al., 2021); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28779002, 28767289, 21681852, 29625052, 12552559, 35483985, 33471991, 35047863, 32427313, 31285527, 29922827) -
Likely pathogenic, criteria provided, single submitterclinical testingInstitute of Medical Genetics and Applied Genomics, University Hospital TรผbingenOct 23, 2020- -
Likely pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenSep 01, 2023ATM: PM1, PM2, PVS1:Moderate -
Ataxia-telangiectasia syndrome Pathogenic:4
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityJan 09, 2019- -
Likely pathogenic, criteria provided, single submitterliterature onlyCounsylJul 25, 2014- -
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpOct 27, 2022Variant summary: ATM c.3G>A (p.Met1Ile) alters the initiation codon and is predicted to result either in absence of the protein or truncation of the encoded protein due to translation initiation at a downstream codon. An alternative downstream in-frame start codon (Met94) is located in the encoded protein. An activation of potential downstream translation initiation site would result in a shortened protein missing the first 93 amino acids from the protein sequence, part of the telomere-length maintenance and DNA damage repair domain (IPR021668). Two of four in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251388 control chromosomes (gnomAD). c.3G>A has been reported in the literature in the compound heterozygous state in individuals affected with Ataxia-Telangiectasia (e.g. Buzin_2003). The variant has also been reported in individuals affected with breast cancer, pancreatic cancer, endometrial cancer, and bladder urothelial carcinoma (Decker_2017, Shindo_2017, Huang_2018, Hutchings_2019, Dorling_2021, Yu_2022, Karpel_2022). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Functional studies on other ATM variants affecting the initiation codon (c.1A>G, c.2T>C) have demonstrated the potential of translation initiation from a downstream AUG codon resulting in a truncated protein. The resulting ATM protein was expressed at low levels and lacked ATM kinase activity (PMIDs: 22146522, 21792198). Nine submitters have provided clinical-significance assessments for this variant to ClinVar after 2014. All laboratories classified the variant as either pathogenic (n=7) or likely pathogenic (n=2). Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingInvitaeJan 13, 2024This sequence change affects the initiator methionine of the ATM mRNA. The next in-frame methionine is located at codon 94. This variant is present in population databases (rs781404312, gnomAD 0.007%). Disruption of the initiator codon has been observed in individuals with ataxia-telangiectasia (PMID: 8845835, 9463314, 12552559, 21792198, 22649200). ClinVar contains an entry for this variant (Variation ID: 188901). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthJul 28, 2020This variant results in the loss of the translation start codon (methionine at codon 1) of the ATM gene. This variant is expected to disrupt the expression of the full-length ATM protein. The next in-frame methionine occurs at codon 94, but it has not been shown if a functional ATM protein product can be produced using p.Met94 as an alternative translation start site. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with ataxia-telangiectasia, breast cancer, and pancreatic cancer (PMID: 12552559, 28767289, 28779002). This variant has been identified in 1/251388 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
Pathogenic, criteria provided, single submittercurationSema4, Sema4May 28, 2021- -
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsSep 01, 2021The p.M1? pathogenic mutation (also known as c.3G>A), located in coding exon 1 of the ATM gene, results from an G to A substitution at nucleotide position 3. This alters the methionine amino acid at the initiation codon. This mutation has been detected in conjunction with a second ATM mutation in two patients with ataxia telangiectasia (Buzin CH et al. Hum. Mutat. 2003 Feb; 21(2):123-31). It was also identified in 2/13087 breast cancer cases and 0/5488 control individuals in the UK as well as a familial pancreatic cancer kindred in the US (Decker B et al. J. Med. Genet. 2017 Nov;54:732-741; Shindo K et al. J. Clin. Oncol. 2017 Oct;35:3382-3390). In addition to the clinical data presented in the literature, since sequence variations that modify the initiation codon (ATG) are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame, this alteration is interpreted as a disease-causing mutation. -
Familial cancer of breast Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingMyriad Genetics, Inc.Jan 10, 2024This variant is considered pathogenic. This variant is located within the gene translation start codon (p.Met1?) and is predicted to result in abnormal protein translation. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 21665257, 9463314, 21792198, 12552559, 22649200, 22146522, 30549301]. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.17
D
BayesDel_noAF
Pathogenic
0.19
Cadd
Uncertain
25
Dann
Uncertain
1.0
Eigen
Uncertain
0.45
Eigen_PC
Uncertain
0.52
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.90
D;D;D;D;D;.;.;.;.;.;D
M_CAP
Pathogenic
0.68
D
MetaRNN
Uncertain
0.65
D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Benign
-0.92
T
MutationTaster
Benign
1.0
D;D
PROVEAN
Uncertain
-2.4
N;N;D;D;.;N;.;.;.;.;.
REVEL
Uncertain
0.48
Sift
Pathogenic
0.0
D;D;D;D;.;D;.;.;.;.;.
Sift4G
Pathogenic
0.0
D;D;D;D;D;D;.;.;.;D;D
Polyphen
0.87, 0.69
.;P;.;.;.;P;P;P;P;P;.
Vest4
0.94, 0.90, 0.96
MutPred
0.99
Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);Gain of catalytic residue at M1 (P = 0.0208);
MVP
0.90
ClinPred
0.98
D
GERP RS
5.1
Varity_R
0.60
gMVP
0.46

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.080
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs781404312; hg19: chr11-108098354; COSMIC: COSV105123483; COSMIC: COSV105123483; API